This article was selected to be shared with PRO+ Short Ideas subscribers - find out more here.
Opportunity Summary
Edwards Lifesciences (EW) is a global leader in TAVR technologies by sales volume and charges premium price for its heart valves. This product leadership and pricing power is reflected in its current share price. But now its leadership in TAVR is seriously threatened because Boston Scientific (BSX) has come up with a comparable product, the LOTUS heart valve, which is arguably better than Edward’s SAPIEN heart valves. Moreover, Medtronic (MDT